Novartis AG Overview
Valuation check: NVS's ROE is 30.5%, above the Healthcare sector average of 21.28%.
Get informed when a big investor buys or sells
+ Follow30.50%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Novartis AG (NVS) currently reports a ROE of 30.5%. That is above the Healthcare sector average of 21.28%. Use the charts on this page to explore Novartis AG's ROE history and peer comparisons.
Novartis AG's ROE of 30.5% is higher than the Healthcare sector average of 21.28%. That is roughly 43.3% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Novartis AG's current 30.5% should be judged against Healthcare norms (sector average: 21.28%) and against NVS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 30.5%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.28%. From there, open related valuation or income-statement pages for Novartis AG, and consider following NVS for alerts when major investors trade the stock.
Novartis AG is classified in the Healthcare sector. On ROE, it currently shows 30.5% versus a sector average near 21.28%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NVS with unrelated industries.
